Drug Trial Radar · NCT06469879
A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients
Last checked: Nov 19, 2026Latest source record: Jul 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
358
Planned (sponsor's estimate)
Start
Sep 2024
Primary completion
Sep 2026
Study completion Sep 2026
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of TQB2450 in combination with anlotinib as maintenance therapy in patients with limited-stage small cell lung cancer who have not progressed after chemoradiotherapy.
Conditions
- Small Cell Lung Cancer Limited Stage
Interventions
TQB2450+AnlotinibDrug
TQB2450 injection test group, 1200 mg/time, strength: 600mg/20 mL, intravenous drip, day 1, every 3 weeks. Anlotinib hydrochloride capsules: 8 mg/time, strength: 10mg/capsule, 8mg/capsule, 6mg/capsule., 1 time a day (QD), continuous use for 2 weeks and stop for 1 week. TQB2450 Injection Placebo (control group): 0 mg/time, strength: 0mg/20 mL, Intravenous Drip, Day 1, every 3 weeks. Anlotinib hydrochloride capsule placebo: 0 mg/time, strength: 0mg/capsule, 1 time a day (QD), continuous use for 2 weeks and stop for 1 week.
TQB2450 placebo + Anlotinib placeboDrug
No drug substance is contained
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) evaluated by the Independent Review Committee (IRC)Time frame: up to 33 months
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Beijing Chest Hospital, Capital Medical University
Beijing, China
Anhui Provincial Hospital
Hefei, Anhui, China
Lanzhou University Second Hospital
Lanzhou, Gansu, China
Guangxi Medical University Cancer Hospital
Nanjing, Guangxi, China
Tangshan People's Hospital
Tangshan, Hebei, China
Harbin Medical University cancer hospital
Harbin, Heilongjiang, China
AnYang Tumor Hospital
Anyang, Henan, China
Xiangyang Central Hospital
Xiangyang, Hubei, China
Hunan Cancer Hospital
Changsha, Hunan, China
The First Hospital of China Medical University
Shenyang, Liaoning, China
Qilu Hospital of Shandong University
Jinan, Shandong, China
Shandong Cancer Hospital
Jinan, Shandong, China
Shanxi Provincial Cancer Hpspital
Taiyuan, Shanxi, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China
The Second People's Hospital of Neijiang
Neijiang, Sichuan, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.